The Commercial Appeal

Over-the-counter home virus test approved by US

- Matthew Perrone

WASHINGTON – The first home test for COVID-19 that doesn’t require a prescripti­on will soon be on U.S. store shelves.

U.S. regulators Tuesday authorized the rapid coronaviru­s test, which can be done entirely at home.

The announceme­nt by the Food and Drug Administra­tion represents another important – though incrementa­l – step in efforts to expand testing options.

Regulators granted emergency use for a similar home test last month, but that one needs a doctor’s prescripti­on.

The agency’s action Tuesday allows sales in places like drugstores “where a patient can buy it, swab their nose, run the test and find out their results in as little as 20 minutes,” said FDA Commission­er Stephen Hahn in a statement.

Initial supplies of the over-thecounter test will be limited. Australian manufactur­er Ellume said it expects to produce 3 million tests next month before ramping up production over the first half of 2021.

A company spokespers­on said the test will be priced around $30 and be available at pharmacies and for purchase online.

The kit includes a nasal swab, a chemical solution and a testing strip. The test connects digitally to a smartphone app that displays the results and then helps interpret them. Users also can connect with a health profession­al via the app.

For months, health experts have stressed the need for fast, widespread home testing so people can screen themselves and avoid contact with others if they have an infection.

But the vast majority of tests still require a nasal swab that must be processed at high-tech laboratori­es. That typically means waiting days for the results.

About 25 tests allow people to collect their own sample at home – a nasal swab or saliva – but then the sample must be processed at a lab. Ellume’s test looks for viral proteins shed by COVID-19, which is different from the gold standard tests that look for the genetic material of the virus.

Like other tests that scan for proteins, FDA officials noted that Ellume’s test can deliver a small percentage of false positive and false negative results.

People who get a negative result but have coronaviru­s symptoms should follow up with a health profession­al, the agency said.

Currently the U.S. is testing nearly 2 million people daily. Most health experts agree the country needs to be testing many times more, and researcher­s at Harvard have pushed for cheap, paper home tests.

Still, Dr. Michael Mina of Harvard called the new test “a great addition” to existing options, though he cautioned that its price could limit access.

“This is a milestone, with reservatio­ns,” Mina said in an email. “I just hope it doesn’t drive more of a wedge between haves and have nots.”

For people with insurance, federal law requires that plans cover the cost of COVID-19 testing.

 ?? ELLUME VIA AP ?? U.S. regulators have approved an at-home, self-administer­ed COVID-19 test developed by an Autralian firm.
ELLUME VIA AP U.S. regulators have approved an at-home, self-administer­ed COVID-19 test developed by an Autralian firm.

Newspapers in English

Newspapers from United States